Anebulo Pharmaceuticals, Inc. (ANEB) Nonoperating Income (Expense) USD 2020 - 2024

Historical data

Taxonomy & unit
us-gaap: USD
Description
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
Summary
Anebulo Pharmaceuticals, Inc. quarterly/annual Nonoperating Income (Expense) history and growth rate from 2020 to 2024.
  • Anebulo Pharmaceuticals, Inc. Nonoperating Income (Expense) for the quarter ending March 31, 2024 was $10.7 K, a 83.8% decline year-over-year.
  • Anebulo Pharmaceuticals, Inc. Nonoperating Income (Expense) for the twelve months ending March 31, 2024 was $116 K.
  • Anebulo Pharmaceuticals, Inc. annual Nonoperating Income (Expense) for 2023 was $51.3 K, a 823% increase from 2022.
  • Anebulo Pharmaceuticals, Inc. annual Nonoperating Income (Expense) for 2022 was $5.56 K.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 $116 K $10.7 K -$55.4 K -83.8% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-15
Q4 2023 $171 K $43.1 K +$56.9 K Oct 1, 2023 Dec 31, 2023 10-Q 2024-02-13
Q3 2023 $114 K $62.9 K +$63.1 K Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-14
Q2 2023 $51.3 K -$767 Apr 1, 2023 Jun 30, 2023 10-K 2023-09-22
Q1 2023 $66.1 K +$62.9 K +1995% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-15
Q4 2022 -$13.8 K Oct 1, 2022 Dec 31, 2022 10-Q 2024-02-13
Q3 2022 -$212 -$1.74 K -114% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-14
Q1 2022 $3.15 K +$6.85 K Jan 1, 2022 Mar 31, 2022 10-Q 2022-05-11
Q3 2021 $1.53 K +$5.56 K Jul 1, 2021 Sep 30, 2021 10-Q 2021-11-12
Q1 2021 -$3.7 K Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-11
Q3 2020 -$4.03 K Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-12
Q2 2020 -$1.29 K Apr 23, 2020 Jun 30, 2020 10-K 2021-09-22
* An asterisk sign (*) next to the value indicates that the value is likely invalid.